In our study, we found positive PD-L1 expression in 87.7% of patients with NPC; 14.3% had 0–1% PD-L1 expression, 47.4% had 1–49% expression while 26% had ≥50% expression. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.